Literature DB >> 23925787

Schizophrenia is a cognitive illness: time for a change in focus.

René S Kahn1, Richard S E Keefe.   

Abstract

Schizophrenia is currently classified as a psychotic disorder. This article posits that this emphasis on psychosis is a conceptual fallacy that has greatly contributed to the lack of progress in our understanding of this illness and hence has hampered the development of adequate treatments. Not only have cognitive and intellectual underperformance consistently been shown to be risk factors for schizophrenia, several studies have found that a decline in cognitive functioning precedes the onset of psychosis by almost a decade. Although the question of whether cognitive function continues to decline after psychosis onset is still debated, it is clear that cognitive function in schizophrenia is related to outcome and little influenced by antipsychotic treatment. Thus, our focus on defining (and preventing) the disorder on the basis of psychotic symptoms may be too narrow. Not only should cognition be recognized as the core component of the disorder, our diagnostic efforts should emphasize the changes in cognitive function that occur earlier in development. Putting the focus back on cognition may facilitate finding treatments for the illness before psychosis ever emerges.

Entities:  

Mesh:

Year:  2013        PMID: 23925787     DOI: 10.1001/jamapsychiatry.2013.155

Source DB:  PubMed          Journal:  JAMA Psychiatry        ISSN: 2168-622X            Impact factor:   21.596


  235 in total

1.  Abnormalities in white matter tracts in the fronto-striatal-thalamic circuit are associated with verbal performance in 22q11.2DS.

Authors:  Carina Heller; Saskia Steinmann; James J Levitt; Nikos Makris; Kevin M Antshel; Wanda Fremont; Ioana L Coman; Stefan R Schweinberger; Thomas Weiß; Sylvain Bouix; Marek R Kubicki; Wendy R Kates; Zora Kikinis
Journal:  Schizophr Res       Date:  2020-10-23       Impact factor: 4.939

2.  Evaluation of a plasticity-based cognitive training program in schizophrenia: Results from the eCaesar trial.

Authors:  Henry W Mahncke; Sarah-Jane Kim; Annika Rose; Catherine Stasio; Peter Buckley; Stanley Caroff; Erica Duncan; Sarah Yasmin; L Fredrik Jarskog; J Steven Lamberti; Keith Nuechterlein; Martin Strassnig; Dawn Velligan; Joseph Ventura; Trina Walker; T Scott Stroup; Richard S E Keefe
Journal:  Schizophr Res       Date:  2019-03-28       Impact factor: 4.939

3.  Early Childhood IQ Trajectories in Individuals Later Developing Schizophrenia and Affective Psychoses in the New England Family Studies.

Authors:  Jessica C Agnew-Blais; Stephen L Buka; Garrett M Fitzmaurice; Jordan W Smoller; Jill M Goldstein; Larry J Seidman
Journal:  Schizophr Bull       Date:  2015-04-22       Impact factor: 9.306

4.  Impaired hippocampal place cell dynamics in a mouse model of the 22q11.2 deletion.

Authors:  Jeffrey D Zaremba; Anastasia Diamantopoulou; Nathan B Danielson; Andres D Grosmark; Patrick W Kaifosh; John C Bowler; Zhenrui Liao; Fraser T Sparks; Joseph A Gogos; Attila Losonczy
Journal:  Nat Neurosci       Date:  2017-09-04       Impact factor: 24.884

5.  Integration of Enhancer-Promoter Interactions with GWAS Summary Results Identifies Novel Schizophrenia-Associated Genes and Pathways.

Authors:  Chong Wu; Wei Pan
Journal:  Genetics       Date:  2018-05-04       Impact factor: 4.562

6.  The Impact of Childhood Adversity on Cognitive Development in Schizophrenia.

Authors:  Ruth Wells; Isabella Jacomb; Vaidy Swaminathan; Suresh Sundram; Danielle Weinberg; Jason Bruggemann; Vanessa Cropley; Rhoshel K Lenroot; Avril M Pereira; Andrew Zalesky; Chad Bousman; Christos Pantelis; Cynthia Shannon Weickert; Thomas W Weickert
Journal:  Schizophr Bull       Date:  2020-01-04       Impact factor: 9.306

7.  Neurocognitive profiles in the prodrome to psychosis in NAPLS-1.

Authors:  Eva Velthorst; Eric C Meyer; Anthony J Giuliano; Jean Addington; Kristin S Cadenhead; Tyrone D Cannon; Barbara A Cornblatt; Thomas H McGlashan; Diana O Perkins; Ming T Tsuang; Elaine F Walker; Scott W Woods; Carrie E Bearden; Larry J Seidman
Journal:  Schizophr Res       Date:  2018-08-02       Impact factor: 4.939

8.  Exercise as Medicine for Mental and Substance Use Disorders: A Meta-review of the Benefits for Neuropsychiatric and Cognitive Outcomes.

Authors:  Garcia Ashdown-Franks; Joseph Firth; Rebekah Carney; Andre F Carvalho; Mats Hallgren; Ai Koyanagi; Simon Rosenbaum; Felipe B Schuch; Lee Smith; Marco Solmi; Davy Vancampfort; Brendon Stubbs
Journal:  Sports Med       Date:  2020-01       Impact factor: 11.136

9.  Neurodevelopmental Genomic Strategies in the Study of the Psychosis Spectrum.

Authors:  Raquel E Gur
Journal:  Nebr Symp Motiv       Date:  2016

Review 10.  Neurocognitive, Neuroprotective, and Cardiometabolic Effects of Raloxifene: Potential for Improving Therapeutic Outcomes in Schizophrenia.

Authors:  Mohammad M Khan
Journal:  CNS Drugs       Date:  2016-07       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.